Company: INMB
Filing Date: 2025-03-07
Form Type: 424B5
Source: 0001213900-25-021719
Chunk: 21

Company: Inmune Bio, Inc.
Filing Date: 2025-03-07
Form: 424B5
Chunk 21
---
’
prior notice from the holder to us, the holder may increase the amount of ownership of outstanding common stock after exercising the holder’s
Second April 2024 Warrants up to 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise,
as such percentage ownership is determined in accordance with the terms of the Second April 2024 Warrants. No fractional shares of common
stock will be issued in connection with the exercise of a Second April 2024 Warrant. In lieu of fractional shares, we will pay the holder
an amount in cash equal to the fractional amount multiplied by the exercise price.

September 2024 Warrants

Duration and Exercise Price

Each September 2024 Warrant
has an initial exercise price of $6.40 per share. The September 2024 Warrants are exercisable on or after March 16, 2025, and will expire
on March 16, 2030, unless accelerated pursuant to the September 2024 Warrant (the “Termination Date”).

After March 16, 2025, subject
to certain conditions, the Termination Date is subject to acceleration upon the occurrence of both (i) the Company’s public announcement
of reporting of positive top line data (EMACC p-value of less than or equal to 0.05) in the Phase 2 Alzheimer’s program of XPro1595
(the “Announcement”) and (ii) the closing price of the Company’s common stock on the trading market on which it is then
traded has equaled or exceeded 200% of the exercise price for fifteen (15) consecutive trading days within one and a half years from the
date of the Announcement (such period, the “Price Condition Measurement Period”) and the dollar amount of the daily trading
volume for seven (7) consecutive trading days commencing on the first day of the Price Condition Measurement Period is at least $5.0 million
per day ((i) and (ii) collectively referred to as the “Acceleration Conditions”). The Company shall provide prompt notice
to the holder upon the Announcement and the Company shall provide prompt notice to the holder upon meeting of the Acceleration Conditions
set forth in (i) and (ii) above (the “Notice”). Following or concurrent with the delivery of the Notice, the Termination Date
shall be accelerated.

Exercisability

The September 2024 Warrants
will be exercisable after the Initial Exercise Date,